Plasma insulin-like growth factor I levels during treatment of congenital adrenal hyperplasia.
We tested the hypotheses that the levels of insulin-like growth factor I (IGF-I) reflect the degree of control during the treatment of patients with congenital adrenal hyperplasia (CAH), and that suppressed IGF-I levels during puberty contribute to decreased adult height. We measured serial IGF-I levels in 26 CAH patients followed over 6 months to 5 years. The control of CAH was variable, with several cases of overtreatment in infancy, and frequent undertreatment in childhood and adolescence. IGF-I levels were quite variable and inconsistent with the control of CAH. Our results suggest that IGF-I levels are not helpful in monitoring CAH patients; IGF-I does not seem to play a role in the growth failure during CAH therapy.
Cavallo
A
A
Department of Pediatrics, Brown University, Providence, R.I.
Furlanetto
R W
RW
Meyer
W J
WJ
D000293:Adolescent; D000312:Adrenal Hyperplasia, Congenital / Q000097:blood* / Q000628:therapy; D000735:Androstenedione / Q000097:blood; D015415:Biomarkers / Q000097:blood; D002648:Child; D002675:Child, Preschool; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007223:Infant; D007334:Insulin-Like Growth Factor I / Q000032:analysis*; D008297:Male
D015415:Biomarkers; D000735:Androstenedione; D007334:Insulin-Like Growth Factor I